Cellbricks Therapeutics has raised €10 million in new funding to accelerate the development of its biofabricated human tissue implants.
The financing includes a €7 million seed round alongside more than €3 million in additional non-dilutive funding currently under negotiation. The round was led by Silicon Roundabout Ventures, with participation from Federal Agency for Breakthrough Innovation and existing investor ACT Venture Partners, along with other long-term backers.
The company will use the capital to advance translational development of its living, vascularized tissue implants, focusing on preclinical validation and moving closer to human clinical studies. Its immediate priorities include progressing its lead adipose tissue implant program and initiating multiple preclinical animal studies.
Cellbricks Therapeutics is targeting major unmet needs in reconstructive surgery, wound healing and trauma care. Its technology aims to provide biological alternatives to synthetic implants, particularly for complex soft tissue defects and applications such as breast reconstruction.
The company’s broader ambition is to enable the development of 3D-bioprinted viable human organs. The current strategy focuses on a stepwise approach, advancing tissue-specific solutions that can survive, integrate and function within the human body as foundational building blocks toward organ replacement.
KEY QUOTES:
“The ambition is clear: restoring functional human tissue and, ultimately, enabling organ replacement. That future is built one disciplined milestone at a time. This funding allows us to reach the next level of validation and to advance living tissue implants that address urgent patient needs now while laying the groundwork for what comes next.”
Alexander Leutner, Co-CEO And Co-Founder, Cellbricks Therapeutics
“Regenerative medicine has talked for a long time about what may one day be possible. The next chapter is about demonstrating what can actually work in relevant models, with living tissues designed to integrate, restore function and move with real credibility towards the clinic.”
Dr. Simon MacKenzie, Co-CEO, Cellbricks Therapeutics
